Blocking of CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritis

Journal of Immunology

Volumn 183, Issue 6, 2009, Pages 3770-3777

  Oflazoglu, Ezogelin ^a   Boursalian, Tamar E ^a   Zeng, Weiping ^a   Edwards, Ana C ^a   Duniho, Steve ^a   McEarchern, Julie A ^a   Law, Che Leung ^a   Gerber, Hans Peter ^a,b   Grewal, Iqbal S ^a  

^a SEATTLE GENETICS INC   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; CD27 ANTIGEN; CD70 ANTIBODY; CD70 ANTIGEN; FC RECEPTOR; UNCLASSIFIED DRUG; AUTOANTIBODY; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; ARTHRITIS; ARTICLE; BONE DESTRUCTION; COMPLEMENT FIXATION; CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; DRUG INDUCED DISEASE; EFFECTOR CELL; GENE TARGETING; HISTOPATHOLOGY; IN VIVO STUDY; INFLAMMATION; JOINT; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION; ANIMAL; ARTHROPATHY; BONE; CARTILAGE; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD27; ANTIGENS, CD70; ARTHRITIS, EXPERIMENTAL; AUTOANTIBODIES; BONE AND BONES; CARTILAGE; DISEASE PROGRESSION; INFLAMMATION; JOINT DISEASES; MALE; MICE;

EID: 70349307047     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901637     Document Type: Article

References (56)

1. Nolte, M. A., R. W. van Olffen, K. P. van Gisbergen, and R. A. van Lier. 2009. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol. Rev. 229: 216-231.
2. Boursalian, T. E., J. A. McEarchern, C. L. Law, and I. S. Grewal. 2009. Targeting CD70 for human therapeutic use. Adv. Exp. Med. Biol. 647: 108-119.
3. Grewal, I. S. 2008. Targeting CD70 for human malignancies. Adv. Exp. Med. Biol. 647: 341-351.
4. Croft, M. 2009. The role of TNF family superfamily members in T-cell function and diseases. Nat. Rev. Immunol. 9: 271-285.
5. Lens, S. M., P. A. Baars, B. Hooibrink, M. H. van Oers, and R. A. van Lier. 1997. Antigen-presenting cell-derived signals determine expression levels of CD70 on primed T cells. Immunology 90: 38-45.
6. Hintzen, R. Q., S. M. Lens, G. Koopman, S. T. Pals, H. Spits, and R. A. van Lier. 1994. CD70 represents the human ligand for CD27. Int. Immunol. 6: 477-480.
7. Hintzen, R. Q., S. M. Lens, M. P. Beckmann, R. G. Goodwin, D. Lynch, and R. A. van Lier. 1994. Characterization of the human CD27 ligand, a novel member of the TNF gene family. J. Immunol. 152: 1762-1773.
8. Akiba, H., Y. Miyahira, M. Atsuta, K. Takeda, C. Nohara, T. Futagawa, H. Matsuda, T. Aoki, H. Yagita, and K. Okumura. 2000. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J. Exp. Med. 191: 375-380. (Pubitemid 30060926)
9. Tesselaar, K., Y. Xiao, R. Arens, G. M. van Schijndel, D. H. Schuurhuis, R. E. Mebius, J. Borst, and R. A. van Lier. 2003. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J. Immunol. 170: 33-40. (Pubitemid 36026120)
10. + T cells. J. Immunol. 174: 710-717.
11. Hintzen, R. Q., R. de Jong, S. M. Lens, and R. A. van Lier. 1994. CD27: marker and mediator of T-cell activation? Immunol. Today 15: 307-311.
12. Lens, S. M., K. Tesselaar, M. H. van Oers, and R. A. van Lier. 1998. Control of lymphocyte function through CD27-CD70 interactions. Semin. Immunol. 10: 491-499.
13. Borst, J., J. Hendriks, and Y. Xiao. 2005. CD27 and CD70 in T cell and B cell activation. Curr. Opin. Immunol. 17: 275-281.
14. Goodwin, R. G., M. R. Alderson, C. A. Smith, R. J. Armitage, T. VandenBos, R. Jerzy, T. W. Tough, M. A. Schoenborn, T. Davis-Smith, K. Hennen, et al. 1993. Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 73: 447-456.
15. de Jong, R., W. A. Loenen, M. Brouwer, L. van Emmerik, E. F. de Vries, J. Borst, and R. A. van Lier. 1991. Regulation of expression of CD27, a T cell-specific member of a novel family of membrane receptors. J. Immunol. 146: 2488-2494.
16. Hintzen, R. Q., R. de Jong, S. M. Lens, M. Brouwer, P. Baars, and R. A. van Lier. 1993. Regulation of CD27 expression on subsets of mature T-lymphocytes. J. Immunol. 151: 2426-2435. (Pubitemid 23264495)
17. van Lier, R. A., J. Borst, T. M. Vroom, H. Klein, P. Van Mourik, W. P. Zeijlemaker, and C. J. Melief. 1987. Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen. J. Immunol. 139: 1589-1596.
18. Hintzen, R. Q., R. A. van Lier, K. C. Kuijpers, P. A. Baars, W. Schaasberg, C. J. Lucas, and C. H. Polman. 1991. Elevated levels of a soluble form of the T cell activation antigen CD27 in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 35: 211-217.
19. + peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J. Exp. Med. 188: 1679-1689.
20. Jacquot, S., T. Kobata, S. Iwata, C. Morimoto, and S. F. Schlossman. 1997. CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 signaling. J. Immunol. 159: 2652-2657. (Pubitemid 127681283)
21. Kobata, T., S. Jacquot, S. Kozlowski, K. Agematsu, S. F. Schlossman, and C. Morimoto. 1995. CD27-CD70 interactions regulate B-cell activation by T cells. Proc. Natl. Acad. Sci. USA 92: 11249-11253.
22. Akiba, H., H. Nakano, S. Nishinaka, M. Shindo, T. Kobata, M. Atsuta, C. Morimoto, C. F. Ware, N. L. Malinin, D. Wallach, et al. 1998. CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-κB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-κB-inducing kinase. J. Biol. Chem. 273: 13353-13358.
23. Ramakrishnan, P., W. Wang, and D. Wallach. 2004. Receptor-specific signaling for both the alternative and the canonical NF-κB activation pathways by NF-κBinducing kinase. Immunity 21: 477-489. (Pubitemid 39370504)
24. Hendriks, J., L. A. Gravestein, K. Tesselaar, R. A. van Lier, T. N. Schumacher, and J. Borst. 2000. CD27 is required for generation and long-term maintenance of T cell immunity. Nat. Immunol. 1: 433-440.
25. + CD4 T cell clones and involved in distinct immunoregulatory functions. J. Immunol. 149: 3208-3216.
26. Hintzen, R. Q., S. M. Lens, K. Lammers, H. Kuiper, M. P. Beckmann, and R. A. van Lier. 1995. Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J. Immunol. 154: 2612-2623.
27. Xiao, Y., J. Hendriks, P. Langerak, H. Jacobs, and J. Borst. 2004. CD27 is acquired by primed B cells at the centroblast stage and promotes germinal center formation. J. Immunol. 172: 7432-7441. (Pubitemid 38747605)
28. Agematsu, K., H. Nagumo, Y. Oguchi, T. Nakazawa, K. Fukushima, K. Yasui, S. Ito, T. Kobata, C. Morimoto, and A. Komiyama. 1998. Generation of plasma cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27/CD70 interaction. Blood 91: 173-180.
29. Arens, R., K. Tesselaar, P. A. Baars, G. M. van Schijndel, J. Hendriks, S. T. Pals, P. Krimpenfort, J. Borst, M. H. van Oers, and R. A. van Lier. 2001. Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNγ-mediated B cell depletion. Immunity 15: 801-812.
30. + T cell formation. J. Exp. Med. 199: 1595-1605.
31. Hendriks, J., Y. Xiao, and J. Borst. 2003. CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool. J. Exp. Med. 198: 1369-1380. (Pubitemid 37392482)
32. Nakajima, A., H. Oshima, C. Nohara, S. Morimoto, S. Yoshino, T. Kobata, H. Yagita, and K. Okumura. 2000. Involvement of CD70-CD27 interactions in the induction of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 109: 188-196.
33. Aramaki, O., N. Shirasugi, Y. Akiyama, S. Shibutani, T. Takayama, M. Shimazu, M. Kitajima, Y. Ikeda, K. Okumura, H. Yagita, and M. Niimi. 2003. CD27/ CD70, CD134/CD134 ligand, and CD30/CD153 pathways are independently essential for generation of regulatory cells after intratracheal delivery of alloantigen. Transplantation 76: 772-776. (Pubitemid 37140217)
34. + antigen-presenting cells control the proliferation and differentiation of T cells in the intestinal mucosa. Nat. Immunol. 6: 698-706.
35. Brugnoni, D., P. Airo, R. Marino, L. D. Notarangelo, R. A. van Lier, and R. Cattaneo. 1997. CD70 expression on T-cell subpopulations: study of normal individuals and patients with chronic immune activation. Immunol. Lett. 55: 99-104. (Pubitemid 27166210)
36. Lee, W. W., Z. Z. Yang, G. Li, C. M. Weyand, and J. J. Goronzy. 2007. Unchecked CD70 expression on T cells lowers threshold for T cell activation in rheumatoid arthritis. J. Immunol. 179: 2609-2615.
37. Oelke, K., Q. Lu, D. Richardson, A. Wu, C. Deng, S. Hanash, and B. Richardson. 2004. Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors. Arthritis Rheum. 50: 1850-1860. (Pubitemid 38725098)
38. + T cells in the periphery of patients with systemic lupus erythematosus. Lupus 14: 598-606.
39. Lu, Q., A. Wu, and B. C. Richardson. 2005. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J. Immunol. 174: 6212-6219. (Pubitemid 40663812)
40. + T cells in MRL/lpr lupus-prone mice. Eur. J. Immunol. 37: 1407-1413.
41. Gilliland, L. K., N. A. Norris, H. Marquardt, T. T. Tsu, M. S. Hayden, M. G. Neubauer, D. E. Yelton, R. S. Mittler, and J. A. Ledbetter. 1996. Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments. Tissue Antigens 47: 1-20.
42. McEarchern, J. A., E. Oflazoglu, L. Francisco, C. F. McDonagh, K. A. Gordon, I. Stone, K. Klussman, E. Turcott, N. van Rooijen, P. Carter, et al. 2007. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 109: 1185-1192.
43. Gorman, C. L., and A. P. Cope. 2008. Immune-mediated pathways in chronic inflammatory arthritis. Best Pract. Res. Clin. Rheumatol. 22: 221-238. (Pubitemid 351606942)
44. Choy, E. H., and G. S. Panayi. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344: 907-916. (Pubitemid 32224400)
45. Cope, A. P. 2008. T cells in rheumatoid arthritis. Arthritis Res. Ther. 10 Suppl 1:S1.
46. Strand, V., R. Kimberly, and J. D. Isaacs. 2007. Biologic therapies in rheumatology: lessons learned, future directions. Nat. Rev. Drug Discov. 6: 75-92. (Pubitemid 46020288)
47. Goronzy, J. J., and C. M. Weyand. 2008. T-cell co-stimulatory pathways in autoimmunity. Arthritis Res. Ther. 10 Suppl 1: S3.
48. O'Dell, J. R. 2004. Therapeutic strategies for rheumatoid arthritis. N. Engl. J. Med. 350: 2591-2602.
49. van der Woude, D., and T. W. Huizinga. 2008. Translating basic research into clinical rheumatology. Best Pract. Res. Clin. Rheumatol. 22: 299-310. (Pubitemid 351606946)
50. Scott, D. L., and G. H. Kingsley. 2006. Tumor necrosis factor inhibitors for rheumatoid arthritis. N. Engl. J. Med. 355: 704-712. (Pubitemid 44244541)
51. Westhovens, R., and P. Verschueren. 2008. Translating co-stimulation blockade into clinical practice. Arthritis Res. Ther. 10 Suppl 1: S4.
52. Malfait, A. M., R. O. Williams, A. S. Malik, R. N. Maini, and M. Feldmann. 2001. Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. Arthritis Rheum. 44: 1215-1224.
53. Williams, R. O., L. Marinova-Mutafchieva, M. Feldmann, and R. N. Maini. 2000. Evaluation of TNF-α and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-α/anti-CD4 therapy. J. Immunol. 165: 7240-7245.
54. Ranges, G. E., S. Sriram, and S. M. Cooper. 1985. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J. Exp. Med. 162: 1105-1110.
55. Hom, J. T., L. D. Butler, P. E. Riedl, and A. M. Bendele. 1988. The progression of the inflammation in established collagen-induced arthritis can be altered by treatments with immunological or pharmacological agents which inhibit T cell activities. Eur. J. Immunol. 18: 881-888.
56. Manocha, M., R. Svend, A. Laouar, G. Liao, A. Bhan, J. Borst, C. Terhorst, and N. Manjunath. 2009. Blocking CD27-CD70 costimulatory pathway suppresses experimental colitis. J. Immunol. 183: 270-276.